Drug Profile
SKL 13865
Alternative Names: SKL ADHD; SKL13865Latest Information Update: 28 Feb 2024
Price :
$50
*
At a glance
- Originator SK biopharmaceuticals
- Class
- Mechanism of Action Adrenergic uptake inhibitors; Dopamine uptake inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Attention-deficit hyperactivity disorder
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for phase-I development in Attention-deficit-hyperactivity-disorder in USA (PO)
- 22 Feb 2022 SKL 13865 is still in phase I trials for attention-deficit-hyperactivity disorder in USA (SK biopharmaceuticals pipeline, February 2022)
- 11 Nov 2021 SKL 13865 licensed to Ignis Therapeutics in Greater China